Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation.
ABO Blood-Group System
/ immunology
Adult
Aged
Antibodies
/ administration & dosage
Blood Group Incompatibility
/ immunology
Female
Follow-Up Studies
Glomerular Filtration Rate
Graft Rejection
/ diagnosis
Graft Survival
Humans
Kidney Failure, Chronic
/ immunology
Kidney Function Tests
Kidney Transplantation
/ adverse effects
Living Donors
/ supply & distribution
Male
Middle Aged
Postoperative Complications
/ diagnosis
Prognosis
Receptors, Interleukin-2
/ antagonists & inhibitors
Retrospective Studies
Risk Factors
Survival Rate
Young Adult
ABO incompatibility
immunoadsorption
kidney transplantation
living donor
rejection
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
23
05
2019
revised:
12
07
2019
accepted:
23
07
2019
pubmed:
2
8
2019
medline:
12
9
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
There is no recommendation regarding the type of induction therapy to use in ABO-incompatible (ABOi) kidney transplantation. The aim of this retrospective study was to compare the outcome of ABOi living donor kidney transplant (LDKT) recipients who received either polyclonal antibodies or anti-interleukin-2 receptor (IL-2R) blockers as an induction agent. All ABOi HLA-compatible patients that received a LDKT between 03/11 and 03/18 in three French transplantation center (Paris Saint-Louis, Paris Necker, and Toulouse) were included in the study. Fifty-eight patients were given polyclonal antibodies and 39 patients received anti-IL-2R blockers. We identified by a Cox proportional hazard model the use of polyclonal antibodies as a protective factor against acute rejection (HR = 0.4, 95%CI [0-0.9], P < .05). However, pathological findings on protocol biopsies at 1 year were similar in both groups, as were patient and graft survivals, renal function, and complications. We conclude that the acute rejection rate was significantly higher in patients given anti-IL-2R blockers compared to polyclonal antibodies. However, in our series, there was no negative impact on mid-term outcome.
Substances chimiques
ABO Blood-Group System
0
Antibodies
0
Receptors, Interleukin-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13681Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev. 2013;27:1-8.
Pankhurst L, Hudson A, Mumford L. The UK National registry of ABOi and HLA antibody incompatible renal transplantation: pretransplant factors associated with outcome in 879 transplants. Transplant direct. 2017;3:e181.
Böhmig GA, Farkas AM, Eskandary F, Wekerle T. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol. 2015;11:732-747.
Opelz G, Morath C, Süsal C, Tran TH, Zeier M, Döhler B. Three-year outcomes following 1420 abo-incompatible living-donor kidney transplants performed after abo antibody reduction: results from 101 centers. Transplantation. 2015;99:400-404.
Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:1320-1327.
Hill P, Cross NB, Barnett A, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017;1:CD004759.
Kalil AC, Florescu MC, Grant W, et al. Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis. Expert review of anti-infective. Therapy. 2014;7:881-896.
Ko EJ, Yu JH, Yang CW, Chung BH. Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study. Transpl Int. 2017;30:1215-1225.
Kumlien G, Wilpert J, Säfwenberg J, Tydén G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation. 2007;84:S17-S19.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.
Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transplant Int. 2013;26:662-672.
Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab. N Engl J Med. 2008;359(16):1736-1738.
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. New Engl J Med. 2006;355:1967-1977.
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA incompatible live donors. N Engl J Med. 2016;374:940-950.
Ishida H, Tanabe K, Ishizuka T, et al. Differences in humoral immunity between a non-rejection group and a rejection group after ABO-incompatible renal transplantation. Transplantation. 2006;81:665-671.
Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation. 2006;13:136-140.
Ando T, Tojimbara T, Sato S, et al. Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol. Transplant Proc. 2004;36:2182-2183.
Lonze BE, Bae S, Kraus ES, et al. Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study. Transplant Int. 2017;30:874-883.
Tyden G, Donauer J, Wadstrom J, et al. Implementation of a Protocol for ABO-Incompatible Kidney Transplantation - A Three-Center Experience with 60 consecutives transplantations. Transplantation. 2007;83:1153-1155.
Lanfranco L, Joly M, Del Bello A, et al. Eculizumab for Thrombotic microangiopathy associated with antibody-mediated rejection after abo-incompatible kidney transplantation. Case Rep Transplant. 2017;2017: 1-6.
De Weerd AE, Betjes M. ABO-incompatible kidney transplant outcomes: a meta-analysis. Clin J Am Soc Nephrol. 2018;13:1234-1243.
Piñeiro GJ, De Sousa-Amorim E, Solé M, et al. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrol. 2018;19:261-270.